2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Australia Leader Award
2022 - Research.com Immunology in Australia Leader Award
2017 - Fellow of the Australian Academy of Science
1995 - Gottschalk Medal, Australian Academy of Science
Mark J. Smyth mainly investigates Immunology, Immune system, Cancer research, Immunotherapy and Cancer. His Interleukin 12 research extends to Immunology, which is thematically connected. His Interleukin 12 study combines topics from a wide range of disciplines, such as Perforin, Natural killer cell, Antigen-presenting cell and Cell biology.
His Cancer research research incorporates themes from Tumor necrosis factor alpha, CD8, Interferon gamma, Adoptive cell transfer and Disease. His work deals with themes such as Melanoma, Cytokine and Oncology, which intersect with Immunotherapy. His Cancer study combines topics in areas such as Cell type, Immunity and Mechanism of action.
His primary scientific interests are in Immunology, Cancer research, Immune system, Cytotoxic T cell and Immunotherapy. His work on Cancer expands to the thematically related Immunology. His study in Cancer research is interdisciplinary in nature, drawing from both Immune checkpoint, T cell, Adoptive cell transfer and Receptor.
His studies in Cytotoxic T cell integrate themes in fields like Molecular biology and T lymphocyte. He combines subjects such as Cytokine and Oncology with his study of Immunotherapy. His work carried out in the field of Interleukin 21 brings together such families of science as Antigen-presenting cell, IL-2 receptor and Cell biology.
Mark J. Smyth spends much of his time researching Cancer research, Immune system, Immunotherapy, Cancer and Immunology. His Cancer research research is multidisciplinary, incorporating elements of Immune checkpoint, Cytotoxic T cell, CD8 and Cancer immunotherapy. His Immune system study incorporates themes from Tumor necrosis factor alpha and Antigen.
The Immunotherapy study combines topics in areas such as T cell, Adjuvant, Oncology and Melanoma. His studies examine the connections between Cancer and genetics, as well as such issues in Adenosine, with regards to Adenosine receptor. His Immunology study integrates concerns from other disciplines, such as Metastasis and Disease.
His primary areas of study are Cancer research, Immune system, Immunology, Immunotherapy and Cancer. His research integrates issues of Immune checkpoint, T cell, Cytotoxic T cell, TIGIT and Cancer immunotherapy in his study of Cancer research. His biological study spans a wide range of topics, including Natural killer cell and Receptor.
As part of one scientific family, Mark J. Smyth deals mainly with the area of Immunology, narrowing it down to issues related to the Oncology, and often Phases of clinical research and Pembrolizumab. The concepts of his Immunotherapy study are interwoven with issues in Cytokine, Immunosuppression, Downregulation and upregulation, Melanoma and Drug resistance. His Cancer research includes elements of Adenosine and Adenosine receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Robert D. Schreiber;Lloyd J. Old;Mark J. Smyth;Mark J. Smyth.
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely;Michael H. Kershaw;Robert D. Schreiber;Mark J. Smyth.
Annual Review of Immunology (2011)
Immune surveillance of tumors.
Jeremy B. Swann;Mark J. Smyth.
Journal of Clinical Investigation (2007)
Functional significance of the perforin/granzyme cell death pathway
Joseph A. Trapani;Mark J. Smyth.
Nature Reviews Immunology (2002)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel;William Vermi;William Vermi;Jeremy B. Swann;Jeremy B. Swann;Nadeen Zerafa.
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli;Lionel Apetoh;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Laetitia Aymeric;Laetitia Aymeric;Laetitia Aymeric.
Nature Medicine (2009)
NKT cells: what's in a name?
Dale I Godfrey;H Robson MacDonald;Mitchell Kronenberg;Mark J Smyth.
Nature Reviews Immunology (2004)
NKT cells: facts, functions and fallacies
Dale I. Godfrey;Kirsten J.L. Hammond;Lynn D. Poulton;Mark J. Smyth.
Immunology Today (2000)
New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape
Deepak Mittal;Matthew M Gubin;Robert D Schreiber;Mark J Smyth;Mark J Smyth.
Current Opinion in Immunology (2014)
Differential tumor surveillance by natural killer (NK) and NKT cells
Mark J. Smyth;Kevin Y. T. Thia;Shayna E.A. Street;Erika Cretney.
Journal of Experimental Medicine (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: